Ms. Steele served as an advisor to Daré Bioscience Operations from the company’s inception in 2015, and following the company’s business combination with Cerulean Pharma in July 2017, she joined the Board of Directors of the renamed company, Daré Bioscience. Ms. Steele is an accomplished biotechnology executive and corporate attorney with over three decades of leadership in public and private life sciences companies. She currently serves on the Board of Directors of Daré Bioscience, Nacuity Pharmaceuticals and Coagulant Therapeutics, bringing deep expertise in governance and corporate strategy. Previously, she was Senior Vice President, General Counsel, and Secretary at InterMune and Vice President of Legal Affairs for North America at Elan Pharmaceuticals, guiding both through major transactions and growth phases. She holds a BA from the University of Colorado, a JD from UC Hastings College of the Law, and an LLM in Taxation from NYU School of Law.